Online inquiry

IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3873MR)

This product GTTS-WQ3873MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ3873MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15507MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ13717MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ11549MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MGA031
GTTS-WQ4142MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ9715MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ2324MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ10130MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ11812MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MK-3475
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW